Devyser Thalassemia v2 is a fast and robust NGS solution designed for the detection of genetic variants in alpha and beta thalassemia. It offers comprehensive coverage of the globin genes HBA1, HBA2, HBB, HBD, HBG1, and HBG2, and includes the detection of single nucleotide variants (SNVs), insertions/deletions (Indels), and copy number variations (CNVs). Additionally, it detects beta-hemoglobin modifiers such as BCL11A and KLF1.

Devyser Thalassemia v2 Workflow

Key Features

Comprehensive variant detection: Identifies relevant genetic variants of alpha and beta thalassemia, as well as their modifiers.
Advanced CNV: Detects complex copy number variations (CNVs) in the alpha and beta globin gene regions, including the α3.7 and α4.2 deletions.
Long-range PCR (LR-PCR): Enables accurate detection of complex deletions in alpha thalassemia.
Low hands-on time: Streamlined workflow for fast results with same-day library preparation.
Thalassemia Analysis 1 Thalassemia Analysis 2

Dedicated software: Provides automated, user-friendly analysis, with options for batch export and efficient variant analysis without the need for bioinformatics expertise.

Devyser Thalassemia Software

Genes Covered

HBA1, HBA2: Alpha-globin genes. HBB: Beta-globin. HBD: Delta-globin. HBG1, HBG2: Gamma-globin. Beta thalassemia modifiers:
KLF1 (whole exons). BCL11A and HBS1L-MYB (point mutations).

Applications and Advantages

Applications

Research: Ideal for research laboratories studying the genetics of thalassemia and its modifiers. Complex variant detection: Including alpha globin deletions and mutations affecting fetal hemoglobin (HbF) production.

System Advantages

High CNV accuracy: Utilizes long-range PCR techniques and coverage analysis to ensure accuracy in CNV detection. Streamlined workflow: Sample library preparation with minimal hands-on time, suitable for high-throughput analysis. Intuitive software: Facilitates the interpretation of genetic data, reducing the need for intensive bioinformatics intervention.
Devyser Thalassemia Performance

Technical Specifications

Sample requirements

Sample type: Human genomic DNA. Requirements: Contaminant-free DNA, adequately concentrated for effective amplification.

Limitations

For research use only (RUO). Results only applicable to the specific processed samples. CNV detection can be affected by parameters such as DNA quality and concentration.

Area:

Hematology, Hereditary Blood Disorders, Hereditary and/or Rare Diseases, Molecular Genetics, Thalassemia

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Solutions (HRS)

Portfolio of hybrid capture-based NGS solutions for the analysis of genes involved in homologous recombination repair (HRR) and the study of alterations associated with the homologous recombination pathway in different types of cancer. The range includes three scalable panels designed to meet different analytical needs: mini HRS, HRS and Extended HRS (ExtHRS). Detailed description Operating…
SOPHIA Genetics
Next Generation Sequencing (NGS)

Homologous Recombination Deficiency (HRD) Solution

Homologous Recombination Deficiency (HRD) Solution NGS- and low-pass whole-genome sequencing (low-pass WGS)-based solution for determining homologous recombination deficiency (HRD) status in ovarian cancer. Operating Principle This comprehensive solution, available as CE-IVD and for Research Use Only (RUO), is designed to support the determination of tumour HRD status in patients with ovarian cancer. It integrates two…
SOPHIA Genetics
Next Generation Sequencing (NGS)